You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Efficacy and Enterococcal Consumption: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Sirius Huang and Version 1 by Myo-Kyoung Kim.

Enterococci are often used in probiotics but can also cause nosocomial infections. As such, enterococcal consumption may have beneficial health effects, but a thorough evaluation of virulence absence and risk of antibiotic resistance spread is needed at the strain level. 

  • enterococci
  • probiotic
  • VRE
  • enterococcal consumption
  • virulence factor
  • antibiotic resistance

1. Introduction

The genus Enterococcus consists of lactic acid bacteria (LAB) found predominantly in the gut of humans and animals. Among enterococcal species, E. faecium and E. faecalis are the predominant species of the human gastrointestinal system. Enterococci are also involved in the fermentation process of various foods, including cheeses and sausages [1]. Additionally, certain species of Enterococcus are utilized as probiotics to maintain healthy gastrointestinal microbiota and reduce gastrointestinal inflammation. They also demonstrate the ability to produce bacteriocins, which are proteins produced by bacteria to inhibit growth or kill other competing bacteria [2,3][2][3]. However, enterococcal strains can carry plasmid-mediated resistance genes, which can be transferred between bacterial species, causing decreased susceptibility to common antibiotics [4]. These plasmid-mediated genes in enterococci have contributed to Vancomycin-Resistant Enterococci (VRE), which are problematic in the clinical setting [5].

2. Safety of Enterococcal Consumption: Virulence and Antibiotic Resistance

2.1. Opportunistic Pathogenicity of Enterococci

Although enterococci are commensal organisms that are part of the natural human gut flora, they have emerged as common pathogens causing nosocomial infections, such as endocarditis, bacteremia, urinary tract infections (UTIs), intra-abdominal and pelvic infections. Nearly 80% of these infections were associated with E. faecalis [42][6]. Most enterococcal strains are harmless, but some of the strains found in clinical settings are pathogenic because hospitals serve as reservoirs for antibiotic-resistant strains [43][7]. Enterococci are opportunistic pathogens, meaning that they are not usually pathogenic, but they can cause infections in individuals with weakened immune systems. Enterococci are harmless in their natural habitats (GI tract) but can exhibit pathogenicity outside this anatomical site [44][8]. For instance, translocation across intestinal mucosal surfaces to other tissues and systems, like the lung, liver, spleen, lymph nodes, and circulatory system, has been linked to numerous diseases and disorders [5]. Manfredo-Vieira et al. demonstrated that the translocation of E. gallinarum into systemic organs induced autoimmune responses in patients with systemic lupus erythematosus and autoimmune hepatitis [45][9]. In addition, Wang et al. showed that the translocation of E. faecalis had potentially mutagenic and carcinogenic effects in a cell culture model through the production of clastogens (chromosome-breaking factors). For example, the clastogen superoxide (O2−) produced by E. faecalis mediated COX-2 expression, which caused macrophage-induced chromosomal instability and DNA damage in neighboring cells. [46][10].

2.2. Virulence Factors and Pathogenicity of Enterococcus in Probiotics

The existence of various virulence factors will lead to the pathogenicity of enterococci. These virulence factors can be classified by their functions: exoenzyme, adherence, exotoxin, immune modulation, and biofilm formation. Table 31 summarizes research investigating virulent factors and their functions.
Table 31.
Virulence factors of enterococci classified by function.
Virulence Factors Classification Type of Research Enterococcus strains Functions Reference
Adhesin to collagen of E. faecalis (Ace) Adherence Cell culture and analysis of clinical isolates from patients with endocarditis E. faecium OG1RF Ability to bind with collagen type I and IV, as well as laminin Nallapareddy et al.,

2000

[47][11]
Cell wall-anchored collagen membrane adhesin (Acm) Adherence Cell culture and analysis of isolates from patients with severe clinical infections E. faecium TX0054

E. faecium TX2535

E. faecium TX2555		 Ability to bind with collagen type I Nallapareddy et al.,

2003

[48][12]
Endocarditis- and biofilm-associated pili (Ebp) Adherence Analysis of isolates from rats E. faecalis OG1RF Contribution to biofilm formation and adherence to fibrinogen Nallapareddy et al.,

2006

[49][13]
Enterococcus collagen-binding adhesin

(EcbA)		 Adherence Cell culture and analysis of hospital-acquired isolates in vitro E. faecalis E1162 Ability to bind with collagen type I, IV, V, and fibrinogen Hendrickx et al.,

2009

[50][14]
E. faecalis antigen A (EfaA) Adherence In vitro analysis of clinical isolates from patients with endocarditis E. faecalis EBH1 Potential function as an adhesin in the endocardium Lowe et al.,

1995

[51][15]
Extracellular surface protein (Esp) Adherence In vivo experiment regarding urinary tract infection with a mouse model E. faecalis MMH94 Colonization and survival in the bladder Shankar et al.,

2001

[52][16]
Promotion aggregation complex

(PrgB)		 Adherence In vitro experiment with PrgB (AS 10) wildtype and PrgB mutant E. faecalis OG1RF Promotion of aggregation and biofilm formation Schmitt et al.,

2018

[53][17]
Second collagen adhesin of E. faecium (Scm) Adherence Cell culture and analysis of endocarditis isolates E. faecium TX0068

E. faecium TX0074		 Ability to bind with specificity to collagen type V Sillanpää et al.,

2008

[54][18]
Serine glutamate repeat A (SgrA) Adherence Cell culture and analysis of hospital-acquired isolates in vitro E. faecium U0317

E. faecium E1162		 Potential contribution to biofilm formation by binding nidogen and fibrinogen Hendrickx et al.,

2009

[50][14]
Gelatinase (GelE) Exoenzyme Cell culture and analysis in vitro E. faecalis (non-specified) Cleavage of complement C3, resulting in activation of the complement system Park et al.,

2008

[55][19]
Serine Protease (SprE) Exoenzyme In vivo experiment with rabbit model of endophthalmitis E. faecalis OG1RF Activation of fsrABC by working together with GelE

(Attenuation of endophthalmitis pathogenesis in rabbits with SprE-deficient mutant)		 Engelbert et al.,

2004

[56][20]
Cytolysin (Cyl) Exotoxin Translocation experiment in vitro E. faecalis JH22, E. faecalis TX1322 Cleavage of complements C3 and iC3b Zeng et al.,

2005

[57][21]
  In vitro analysis of clinical isolates in patients E. faecalis (non-specified) Higher occurrence of Cyl among clinical pathogens Huycke et al.,

1995

[58][22]
Biofilm on plastic D (BopD) Biofilm In vivo experiment with mice E. faecalis T9,

E. faecalis 10D5,

E. faecalis TDM		 Contribution to biofilm formation Creti et al.,

2006

[59][23]
Quorum-sensing complex

(FsrABC)		 Biofilm Comparative Transcriptional Analysis E. faecalis OG1RF,

E. faecalis TX5266		 Encoding of a two-component signal transduction system for initiation of quorum sensing Bourgogne et al.,

2006

[60][24]
Capsular polysaccharides (Cps) Immune Modulation Cell culture and analysis in vitro E. faecalis V583,

E. faecalis LT02,

E. faecalis LT06		 Higher resistance to opsonophagocytosis Thurlow et al.,

2009

[61][25]
None of the above virulence factors have been reported in enterococci used in probiotics.
Despite growing concerns over the pathogenicity of enterococci in hospital settings, no reports have demonstrated virulence factors in enterococcal probiotics. Domann et al. sequenced and compared E. faecalis contained in the probiotic Symbioflor 1® to clinical VRE isolates. E. faecalis strains in Symbioflor 1 were found to lack gene coding for essential virulence factors, such as cyl and esp. The E. faecium T110, a component of the probiotic BIO-THREE®, was sequenced completely and compared to pathogenic and non-pathogenic enterococcal strains. The gene encoding virulence factors were not found in the genome of E. faecium T110. The genome was noticeably different from the pathogenic strains found in hospitals, which included VRE and pathogenicity genes. Of the 40 enterococcal virulence genes established in the VFDB database (http://www.mgc.ac.cn/VFs/main.htm (accessed on 30 May 2023), 32 genes were missing in the T110 genome, affirming its safety as a non-pathogenic strain. The eight virulence genes present in the genome were not well-characterized and did not seem to contribute much to its pathogenicity [62][26].

2.3. Antibiotic Resistance

Avoparcin, a glycopeptide antibiotic similar to vancomycin, has been used as a growth promoter in livestock feed since the 1970s. The use of avoparcin coincided with the emergence of VRE outbreaks in hospitals. This chain of events suggests the possibility of VRE originating from antibiotic use in livestock, which subsequently spread to humans and hospitals through consumption [63][27]. Enterococcal species can be divided into two major categories based on their susceptibility to antibiotics: clade A and clade B. Clade B strains are susceptible to antibiotics (i.e., ampicillin and vancomycin) and, therefore, are not problematic in treatment against enterococci. Clade A strains, on the other hand, are hospital-derived strains that have diverged from Clade B strains and have adapted antibiotic resistance to various antibiotics, such as ampicillin and vancomycin [63,64][27][28]. Persistent use of antibiotics in hospitals and veterinary medicine has created multi-drug-resistant strains of enterococci that may be problematic [5]. These multi-drug resistant strains may spread in hospital settings, mainly through the hands of healthcare workers as well as medical equipment, leading to problematic infections [43][7]. Of particular concern is the increase in the incidence of vancomycin-resistant strains, with over 30% of all nosocomial enterococcal infections having resistance to this antibiotic as of 2019 (CDC). Vancomycin is often used to treat ampicillin-resistant pathogens [42][6]. Therefore, VRE, when pathogenic, has been associated with higher mortality in patients after undergoing hematopoietic cell transplantation [65][29]. Vancomycin resistance is encoded by specific gene clusters with nine variants (vanA, vanB, vanC, vanD, vanE, vanG, vanL, vanM, vanN), which can be identified by PCR or DNA sequencing. [64][28]. The different variants display varying levels of resistance to vancomycin and similar glycopeptide antibiotics. VanA and B are commonly linked to high levels of resistance, whereas vanC, D, E, G, L, M, and N typically demonstrate resistance at lower levels. Each variant employs a unique mechanism to confer resistance to vancomycin. For instance, vanA, B, D, E, L, M, and N are associated with the production of modified peptidoglycan, resulting in reduced affinity towards vancomycin. On the other hand, vanC generates an altered target site that vancomycin struggles to bind effectively, while vanG combines the synthesis of modified peptidoglycan precursors with the alteration of the target site. Complete sequencing of two probiotic strains, E. faecium T110 (BIO-THREE®) and E. faecalis (Symbioflor 1), showed the absence of antibiotic resistance genes [62,63][26][27]. Linezolid, daptomycin, and tigecycline are medications that can treat VRE. However, resistance to these three agents has emerged. According to the global Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) linezolid surveillance monitoring program, the number of linezolid-resistant enterococci (LRE) isolates has increased from 420 in 2002 to 813 in 2014. Similarly, the US Linezolid Experience and Accurate Determination of Resistance (LEADER) surveillance monitoring program reported that LRE faecium increased from 428 in 2004 to 589 in 2014, while LRE faecalis isolates increased from 196 to 239 in 2014 [66][30]. The prevalence of E. faecalis strains resistant to linezolid was found to be 2.8% in Asia, whereas, in the Americas, the prevalence of linezolid-resistant E. faecium was observed to be 3.4% [67][31]. The primary causes of LRE involve changes in the genetic material of the bacteria. These changes occur through mutations in specific genes responsible for producing 23S ribosomal RNA and regulatory genes that encode ribosomal proteins, namely rplC, D, and lV. These mutations result in the replacement of certain amino acids in various ribosomal proteins, including L3, L4, and L22 [68,69,70][32][33][34]. Daptomycin-resistant Enterococcus (DRE) has also been reported. Based on a meta-analysis in 2021 by Dadash et al., the prevalence of DRE (9%) is higher than that of LRE (2.2%). Multiple DRE mechanisms of resistance have been reported. However, two major categories of genes are found in DRE. These consist of regulatory genes for cell-envelope homeostasis and stress response, as well as genes that code for enzymes involved in the phospholipids of the cell membrane. Genes found in DRE faecalis are cls, liaFSR, and gdpD, whereas genes found in DRE faecium are cls, liaSR, and yycFG [71][35]. Tigecycline has been marked as a potential treatment option for complex soft tissue and intra-abdominal infections. However, it cannot be used for bloodstream infections due to inadequate antibiotic concentration in the bloodstream [72][36]. Dadash et al. also reported tigecycline-resistant Enterococcus (TRE) prevalence rates in Europe. TRE faecium was 3.9% and TRE faecalis was 0.4 [67][31]. Major genes that cause TRE are tet (M) and tet (L). Tet (M) is a ribosomal protection protein that alters the binding site of tigecycline, whereas tet (L) is an MFS-type efflux pump [71,72][35][36]. These tetracycline resistance genes also confer resistance to tigecycline [73][37]. Regarding the antibiotic-resistant risk of probiotic enterococci, no published research that sequences probiotic enterococci for the detection of these LRE, DRE, or DRE-related genes has been conducted.

2.4. Concern of Transfer of Virulence and Antibiotic Resistance

Enterococcal strains currently used in probiotics are not pathogenic, nor confer resistance to antibiotics. However, there is growing concern regarding the potential transfer of virulence and antibiotic-resistance genes between different enterococcal strains. Enterococci have a notable characteristic of possessing mobile genetic elements such as plasmids and transposons, which facilitate the efficient transfer of genes. This feature drives the evolution of certain strains, enabling them to adapt to different antibiotics found in clinical settings [74][38]. For instance, enterococcal strains can transfer genetic material like antibiotic resistance or virulence factors to each other or to other strains through the transfer of conjugative plasmids [5]. An example of such a transfer occurred in a study by de Niederhäusern et al., where they successfully transferred the vanA gene (associated with vancomycin resistance) from VRE to Staphylococcus aureus through the horizontal transfer of the Tn1546 transposon containing vanA. This discovery raised concerns about the horizontal transfer of vancomycin resistance, highlighting that VRE strains are capable of transferring their resistance to other pathogenic strains [75][39]. Another instance involved a clade B-classified E. faecium strain without vancomycin resistance. This clade B strain was found to possess the vanN gene and exhibited inducible vancomycin resistance. This finding suggests the potential transfer of vancomycin resistance from clade A to clade B strains, indicating that the extent of vancomycin resistance may be underestimated, especially in enterococcal strains previously described as lacking antibiotic resistance [64][28]. The highly efficient mechanism of gene transfer implies that a harmless enterococcal strain can acquire virulence or antibiotic resistance through conjugation with a pathogenic strain. In the case of probiotics, where enterococci are consumed in significant quantities, a large population of recipient bacteria is available for the transfer of virulence or antibiotic-resistance genes. This transfer can occur, for example, from pathogenic strains present in the human gastrointestinal tract to harmless probiotic strains [76][40]. Such transfer events can lead to the evolution of pathogenic or antibiotic-resistant probiotic strains, which can potentially cause problematic infections. Olanrewaju et al. showed that conjugal transfer of resistance genes could result in an effect of biofiltration in the guts of zooplankton Daphnia magna and D. pulex. PCR and DNA sequencing was used to confirm that filter feeding in aquatic environments could lead to in vivo conjugative transfer of vanA resistance genes in Daphnia. These results showed that host enterococcal strains in Daphnia can acquire vanA simply through the consumption of vanA-containing bacteria in the aquatic environment. Such conclusions raise the possibility of humans being the end host of resistant enterococcal strains through the food chain [77][41]. In addition, Moubareck et al. demonstrated in vitro and in vivo conjugative transfer of the vanA resistance gene from vancomycin-resistant enterococcal strains isolated from pigs to vancomycin-susceptible human fecal isolates in gnotobiotic mice. The transfer event occurred in human isolates only 5 h after inoculation with the donor strain, suggesting that human bacteria may be able to acquire vancomycin resistance from enterococci of animal origin in a short time frame [78][42]. These findings suggest that the transfer of vancomycin resistance to human hosts is possible. Therefore, it is crucial to carefully monitor enterococcal strains currently deemed “safe” for any potential emergence of virulence or antibiotic resistance. Genetic changes can render these strains pathogenic at any time point in the future [74][38].

References

  1. Hanchi, H.; Mottawea, W.; Sebei, K.; Hammami, R. The Genus Enterococcus: Between Probiotic Potential and Safety Concerns—An Update. Front. Microbiol. 2018, 9, 1791.
  2. Bhardwaj, A.; Gupta, H.; Kapila, S.; Kaur, G.; Vij, S.; Malik, R.K. Safety Assessment and Evaluation of Probiotic Potential of Bacteriocinogenic Enterococcus Faecium KH 24 Strain under in Vitro and in Vivo Conditions. Int. J. Food Microbiol. 2010, 141, 156–164.
  3. Dobson, A.; Cotter, P.D.; Ross, R.P.; Hill, C. Bacteriocin Production: A Probiotic Trait? Appl. Environ. Microbiol. 2012, 78, 1–6.
  4. Moritz, E.M.; Hergenrother, P.J. Toxin–Antitoxin Systems Are Ubiquitous and Plasmid-Encoded in Vancomycin-Resistant Enterococci. Proc. Natl. Acad. Sci. USA 2007, 104, 311–316.
  5. Ferchichi, M.; Sebei, K.; Boukerb, A.M.; Karray-Bouraoui, N.; Chevalier, S.; Feuilloley, M.G.J.; Connil, N.; Zommiti, M. Enterococcus spp.: Is It a Bad Choice for a Good Use—A Conundrum to Solve? Microorganisms 2021, 9, 2222.
  6. Ben Braïek, O.; Smaoui, S. Enterococci: Between Emerging Pathogens and Potential Probiotics. Biomed Res. Int. 2019, 2019, 1–13.
  7. Krawczyk, B.; Wityk, P.; Gałęcka, M.; Michalik, M. The Many Faces of Enterococcus spp.—Commensal, Probiotic and Opportunistic Pathogen. Microorganisms 2021, 9, 1900.
  8. Ramos, S.; Silva, V.; Dapkevicius, M.; Igrejas, G.; Poeta, P. Enterococci, from Harmless Bacteria to a Pathogen. Microorganisms 2020, 8, 1118.
  9. Manfredo-Vieira, S.; Hiltensperger, M.; Kumar, V.; Zegarra-Ruiz, D.; Dehner, C.; Khan, N.; Costa, F.R.C.; Tiniakou, E.; Greiling, T.; Ruff, W.; et al. Translocation of a Gut Pathobiont Drives Autoimmunity in Mice and Humans. Science 2018, 359, 1156–1161.
  10. Wang, X.; Huycke, M.M. Extracellular Superoxide Production by Enterococcus Faecalis Promotes Chromosomal Instability in Mammalian Cells. Gastroenterology 2007, 132, 551–561.
  11. Nallapareddy, S.R.; Singh, K.V.; Duh, R.-W.; Weinstock, G.M.; Murray, B.E. Diversity of Ace, a Gene Encoding a Microbial Surface Component Recognizing Adhesive Matrix Molecules, from Different Strains of Enterococcus Faecalis and Evidence for Production of Ace during Human Infections. Infect. Immun. 2000, 68, 5210–5217.
  12. Nallapareddy, S.R.; Weinstock, G.M.; Murray, B.E. Clinical Isolates of Enterococcus Faecium Exhibit Strain-Specific Collagen Binding Mediated by Acm, a New Member of the MSCRAMM Family: An E. Faecium Collagen-Binding Adhesin. Mol. Microbiol. 2003, 47, 1733–1747.
  13. Nallapareddy, S.R.; Singh, K.V.; Sillanpaa, J.; Garsin, D.A.; Hook, M.; Erlandsen, S.L.; Murray, B.E. Endocarditis and Biofilm-Associated Pili of Enterococcus Faecalis. J. Clin. Investig. 2006, 116, 2799–2807.
  14. Hendrickx, A.P.A.; Van Luit-Asbroek, M.; Schapendonk, C.M.E.; Van Wamel, W.J.B.; Braat, J.C.; Wijnands, L.M.; Bonten, M.J.M.; Willems, R.J.L. SgrA, a Nidogen-Binding LPXTG Surface Adhesin Implicated in Biofilm Formation, and EcbA, a Collagen Binding MSCRAMM, Are Two Novel Adhesins of Hospital-Acquired Enterococcus Faecium. Infect. Immun. 2009, 77, 5097–5106.
  15. Lowe, A.M.; Lambert, P.A.; Smith, A.W. Cloning of an Enterococcus Faecalis Endocarditis Antigen: Homology with Adhesins from Some Oral Streptococci. Infect. Immun. 1995, 63, 703–706.
  16. Shankar, N.; Lockatell, C.V.; Baghdayan, A.S.; Drachenberg, C.; Gilmore, M.S.; Johnson, D.E. Role of Enterococcus Faecalis Surface Protein Esp in the Pathogenesis of Ascending Urinary Tract Infection. Infect. Immun. 2001, 69, 4366–4372.
  17. Schmitt, A.; Jiang, K.; Camacho, M.I.; Jonna, V.R.; Hofer, A.; Westerlund, F.; Christie, P.J.; Berntsson, R.P.-A. PrgB Promotes Aggregation, Biofilm Formation, and Conjugation through DNA Binding and Compaction: PrgB Structure and DNA-Binding Activity. Mol. Microbiol. 2018, 109, 291–305.
  18. Sillanpää, J.; Nallapareddy, S.R.; Prakash, V.P.; Qin, X.; Höök, M.; Weinstock, G.M.; Murray, B.E. Identification and Phenotypic Characterization of a Second Collagen Adhesin, Scm, and Genome-Based Identification and Analysis of 13 Other Predicted MSCRAMMs, Including Four Distinct Pilus Loci, in Enterococcus Faecium. Microbiology 2008, 154, 3199–3211.
  19. Park, S.Y.; Shin, Y.P.; Kim, C.H.; Park, H.J.; Seong, Y.S.; Kim, B.S.; Seo, S.J.; Lee, I.H. Immune Evasion of Enterococcus Faecalis by an Extracellular Gelatinase That Cleaves C3 and IC3b. J. Immunol. 2008, 181, 6328–6336.
  20. Engelbert, M.; Mylonakis, E.; Ausubel, F.M.; Calderwood, S.B.; Gilmore, M.S. Contribution of Gelatinase, Serine Protease, and Fsr to the Pathogenesis of Enterococcus Faecalis Endophthalmitis. Infect. Immun. 2004, 72, 3628–3633.
  21. Zeng, J.; Teng, F.; Murray, B.E. Gelatinase Is Important for Translocation of Enterococcus Faecalis across Polarized Human Enterocyte-Like T84 Cells. Infect. Immun. 2005, 73, 1606–1612.
  22. Huycke, M.M.; Gilmore, M.S. Frequency of Aggregation Substance and Cytolysin Genes among Enterococcal Endocarditis Isolates. Plasmid 1995, 34, 152–156.
  23. Creti, R.; Koch, S.; Fabretti, F.; Baldassarri, L.; Huebner, J. Enterococcal Colonization of the Gastrointestinal Tract: Role of Biofilm and Environmental Oligosaccharides. BMC Microbiol. 2006, 6, 60.
  24. Bourgogne, A.; Hilsenbeck, S.G.; Dunny, G.M.; Murray, B.E. Comparison of OG1RF and an Isogenic FsrB Deletion Mutant by Transcriptional Analysis: The Fsr System of Enterococcus Faecalis Is More than the Activator of Gelatinase and Serine Protease. J. Bacteriol. 2006, 188, 2875–2884.
  25. Thurlow, L.R.; Thomas, V.C.; Fleming, S.D.; Hancock, L.E. Enterococcus Faecalis Capsular Polysaccharide Serotypes C and D and Their Contributions to Host Innate Immune Evasion. Infect. Immun. 2009, 77, 5551–5557.
  26. Domann, E.; Hain, T.; Ghai, R.; Billion, A.; Kuenne, C.; Zimmermann, K.; Chakraborty, T. Comparative Genomic Analysis for the Presence of Potential Enterococcal Virulence Factors in the Probiotic Enterococcus Faecalis Strain Symbioflor 1. Int. J. Med. Microbiol. 2007, 297, 533–539.
  27. Leavis, H.L.; Bonten, M.J.; Willems, R.J. Identification of High-Risk Enterococcal Clonal Complexes: Global Dispersion and Antibiotic Resistance. Curr. Opin. Microbiol. 2006, 9, 454–460.
  28. Lebreton, F.; Valentino, M.D.; Schaufler, K.; Earl, A.M.; Cattoir, V.; Gilmore, M.S. Transferable Vancomycin Resistance in Clade B Commensal-Type Enterococcus Faecium. J. Antimicrob. Chemother. 2018, 73, 1479–1486.
  29. Papanicolaou, G.A.; Ustun, C.; Young, J.-A.H.; Chen, M.; Kim, S.; Woo Ahn, K.; Komanduri, K.; Lindemans, C.; Auletta, J.J.; Riches, M.L.; et al. Bloodstream Infection Due to Vancomycin-Resistant Enterococcus Is Associated With Increased Mortality After Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome: A Multicenter, Retrospective Cohort Study. Clin. Infect. Dis. 2019, 69, 1771–1779.
  30. Bi, R.; Qin, T.; Fan, W.; Ma, P.; Gu, B. The Emerging Problem of Linezolid-Resistant Enterococci. J. Glob. Antimicrob. Resist. 2018, 13, 11–19.
  31. Dadashi, M.; Sharifian, P.; Bostanshirin, N.; Hajikhani, B.; Bostanghadiri, N.; Khosravi-Dehaghi, N.; Van Belkum, A.; Darban-Sarokhalil, D. The Global Prevalence of Daptomycin, Tigecycline, and Linezolid-Resistant Enterococcus Faecalis and Enterococcus Faecium Strains From Human Clinical Samples: A Systematic Review and Meta-Analysis. Front. Med. 2021, 8, 720647.
  32. Chen, Q.; Yin, D.; Li, P.; Guo, Y.; Ming, D.; Lin, Y.; Yan, X.; Zhang, Z.; Hu, F. First Report Cfr and OptrA Co-Harboring Linezolid-Resistant Enterococcus Faecalis in China. Ind. Diamond Rev. 2020, 13, 3919–3922.
  33. Tsilipounidaki, K.; Gerontopoulos, A.; Papagiannitsis, C.; Petinaki, E. First Detection of an OptrA-Positive, Linezolid-Resistant ST16 Enterococcus Faecalis from Human in Greece. New Microbes New Infect. 2019, 29, 100515.
  34. Liu, Y.; Wang, Y.; Schwarz, S.; Li, Y.; Shen, Z.; Zhang, Q.; Wu, C.; Shen, J. Transferable Multiresistance Plasmids Carrying Cfr in Enterococcus spp. from Swine and Farm Environment. Antimicrob. Agents Chemother. 2013, 57, 42–48.
  35. Tran, T.T.; Munita, J.M.; Arias, C.A. Mechanisms of Drug Resistance: Daptomycin Resistance: Daptomycin Resistance. Ann. N. Y. Acad. Sci. 2015, 1354, 32–53.
  36. Fiedler, S.; Bender, J.K.; Klare, I.; Halbedel, S.; Grohmann, E.; Szewzyk, U.; Werner, G. Tigecycline Resistance in Clinical Isolates of Enterococcus faecium Is Mediated by an Upregulation of Plasmid-Encoded Tetracycline Determinants Tet (L) and Tet (M). J. Antimicrob. Chemother. 2016, 71, 871–881.
  37. Linkevicius, M.; Sandegren, L.; Andersson, D. Potential of Tetracycline Resistance Proteins To Evolve Tigecycline Resistance. Antimicrob. Agents Chemother. 2016, 60, 789–796.
  38. Franz, C.M.A.P.; Huch, M.; Abriouel, H.; Holzapfel, W.; Gálvez, A. Enterococci as Probiotics and Their Implications in Food Safety. Int. J. Food Microbiol. 2011, 151, 125–140.
  39. De Niederhäusern, S.; Bondi, M.; Messi, P.; Iseppi, R.; Sabia, C.; Manicardi, G.; Anacarso, I. Vancomycin-Resistance Transferability from VanA Enterococci to Staphylococcus Aureus. Curr. Microbiol. 2011, 62, 1363–1367.
  40. Eaton, T.J.; Gasson, M.J. Molecular Screening of Enterococcus Virulence Determinants and Potential for Genetic Exchange between Food and Medical Isolates. Appl. Environ. Microbiol. 2001, 67, 1628–1635.
  41. Olanrewaju, T.O.; McCarron, M.; Dooley, J.S.G.; Arnscheidt, J. Transfer of Antibiotic Resistance Genes between Enterococcus Faecalis Strains in Filter Feeding Zooplankton Daphnia Magna and Daphnia Pulex. Sci. Total Environ. 2019, 659, 1168–1175.
  42. Moubareck, C.; Bourgeois, N.; Courvalin, P.; Doucet-Populaire, F. Multiple Antibiotic Resistance Gene Transfer from Animal to Human Enterococci in the Digestive Tract of Gnotobiotic Mice. Antimicrob. Agents Chemother. 2003, 47, 2993–2996.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Academic Video Service
Feedback